EVOMMUNE INC (EVMN)
Health Care · Clinical-stage biopharmaceutical / immunology · NYSE
Evommune is an immunology-focused clinical-stage biotech developing novel product candidates EVO756 and EVO301 to address unmet disease needs.
What EVOMMUNE INC does
Evommune is an early-stage clinical-stage biotechnology company developing immunology-focused product candidates. The company's lead programs include EVO756 and EVO301, which are currently in clinical development. Evommune is unprofitable and pre-revenue, requiring additional funding to advance its product candidates toward regulatory approval and potential commercialization.
Themes: ["immunology","clinical-stage development","biopharmaceutical R&D"]
Fundamentals
- Price$13.51 as of 2026-07-09 close
- Market cap$477M as of 2026-07-10
- 1-year return-22.6% as of 2026-07-09 close
- Net margin-606.2% as of 2026-07-10
- ROE-33.5% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+85.7% as of 2026-07-10
- Beta-0.48 as of 2026-07-10
Key risks (from latest filing)
["Clinical trial success and timing risks for lead candidates EVO756 and EVO301","Substantial capital requirements; company must raise additional funding before generating product revenues","Regulatory approval uncertainty and dependence on establishing adequate safety/efficacy profiles for product candidates"]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.